热门资讯> 正文
AnaptysBio制定1亿美元股票回购计划
2025-11-21 17:22
- AnaptysBio (ANAB) board has authorized an amended stock repurchase plan to buy back up to $100.0 million of its outstanding common stock.
- This amendment is in addition to the $6.4 million that remained as of Nov. 20, 2025 under the current $75 million plan, of which Anaptys has repurchased 3.44M (11.2% shares outstanding before the start of this repurchase plan).
- Excluding any additional potential purchases under this stock repurchase plan, Anaptys expects to end 2025 with ~$300 million in cash, cash equivalents and investments, including an anticipated accrual of a one-time $75 million commercial sales milestone in Q4 2025 due from GSK once Jemperli achieves $1 billion in worldwide net sales.
- ANAB --2.25% premarket to $36.81
- Source: Press Release
More on AnaptysBio
- AnaptysBio: Maintaining 'Hold' As RA Program Still In Play With ANB033 Advancement
- AnaptysBio, Inc. (ANAB) ANB033 (CD122 antagonist) Virtual Investor Event - Slideshow
- AnaptysBio, Inc. (ANAB) ANB033 (CD122 antagonist) Virtual Investor Event Transcript
- AnaptysBio posts mid-stage trial setback for lead asset in ulcerative colitis
- AnaptysBio splits operations into two companies
推荐文章
美股机会日报 | 降息有戏？美联储“三把手”威廉姆斯称仍有降息空间；木头姐加仓英伟达
一周财经日历 | 迟来40天！美国9月PPI下周公布；阿里、美团、蔚来等财报压轴登场
财报前瞻 | 股价连续调整！阿里能否交出超预期财报提振信心？AI和云或将扛起增长大旗
一周IPO | 超购近2000倍！量化派火热招股中；创新实业下周一上市；遇见小面通过聆讯
港股异动 | 联想集团午后一度涨1%，业绩超预期，中金、高盛等看好其供应链议价能力
“木头姐”旗舰基金自8月份以来首次买入英伟达股票
AI豪赌的代价：甲骨文(ORCL.US)CDS成本飙升2倍，成对冲AI崩盘新工具
从折价到高光：港股科技板块，AI时代的中国资产“黄金坑”
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
